DF
REGN icon

Donoghue Forlines’s Regeneron Pharmaceuticals REGN Stock Holding History

Donoghue Forlines’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-456
Closed -$375K – 271
2023
Q1 		$375K Sell
456
-45
-9% -$33.9K 0.13% 173
2022
Q4 		$361K Sell
501
-208
-29% -$153K 0.13% 183
2022
Q3 		$488K Sell
709
-1,616
-70% -$1.02M 0.18% 103
2022
Q2 		$1.37M Buy
2,325
+1,091
+88% +$709K 0.36% 54
2022
Q1 		$862K Buy
+1,234
New +$781K 0.19% 175
2020
Q3 		– Sell
-2,308
Closed -$1.44M – 137
2020
Q2 		$1.44M Buy
+2,308
New +$1.31M 0.38% 43
2019
Q2 		– Sell
-6,604
Closed -$2.71M – 205
2019
Q1 		$2.71M Buy
+6,604
New +$2.72M 0.27% 57
2018
Q4 		– Sell
-6,631
Closed -$2.68M – 124
2018
Q3 		$2.68M Buy
+6,631
New +$2.52M 0.21% 82

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return